Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors
Figure 1
Comparison of arsenic trioxide and cisplatin enhanced thermoradiotherapy of FSaII fibrosarcoma tumors applied every 4 days as indicated by the arrows on the -axis. Cisplatin was given at 2 mg/kg, while ATO was given at 8 mg/kg. Radiation fractions were 5 Gy, and hyperthermia was applied at 42.5°C (60 min). In the dual- or trimodality treatment groups, radiation was given first, followed by ATO or cisplatin injection within 30 min and hyperthermia was applied beginning 2 h after the completion of radiation. = 5–7 mice per group. Errors bars represent 1 SEM.